Valion Bio, Inc.
VBIO· Nasdaq
VBIOValion Bio, Inc.
Filed Aug 15, 2022 · 10-Q · 46 days after period end · 0001410578-22-002554
| Metric | Q2 2022 | Q2 2021 |
|---|---|---|
| Revenue | $528.00K | $268.00K |
| Net Income | -$3.02M | -$1.09M |
| EPS Diluted | -$0.32 | -$0.46 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 15, 2022 · 46 d after period end
